216 related articles for article (PubMed ID: 35241544)
21. The preoperative geriatric nutritional risk index predicts long-term prognosis in elderly locally advanced rectal cancer patients: a two-center retrospective cohort study.
Lu S; Li X; Li X; Zhang Q; Wang Y; Peng R; Fu W; Wang H
Aging Clin Exp Res; 2023 Feb; 35(2):311-321. PubMed ID: 36399323
[TBL] [Abstract][Full Text] [Related]
22. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
23. Geriatric nutritional risk index predicts all-cause deaths in heart failure with preserved ejection fraction.
Nishi I; Seo Y; Hamada-Harimura Y; Yamamoto M; Ishizu T; Sugano A; Sato K; Sai S; Obara K; Suzuki S; Koike A; Aonuma K; Ieda M;
ESC Heart Fail; 2019 Apr; 6(2):396-405. PubMed ID: 30706996
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
25. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Taura K; Seno H
J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):498-507. PubMed ID: 33787071
[TBL] [Abstract][Full Text] [Related]
26. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
Rapposelli IG; Shimose S; Kumada T; Okamura S; Hiraoka A; Di Costanzo GG; Marra F; Tamburini E; Forgione A; Foschi FG; Silletta M; Lonardi S; Masi G; Scartozzi M; Nakano M; Shibata H; Kawata K; Pellino A; Vivaldi C; Lai E; Takata A; Tajiri K; Toyoda H; Tortora R; Campani C; Viola MG; Piscaglia F; Conti F; Fulgenzi CAM; Frassineti GL; Rizzato MD; Salani F; Astara G; Torimura T; Atsukawa M; Tada T; Burgio V; Rimini M; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Aug; 6(4):100190. PubMed ID: 34144271
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
28. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib.
Shimamura Y; Abe K; Maeda T; Matsui T; Ishiguro A; Takizawa H
In Vivo; 2021; 35(3):1647-1653. PubMed ID: 33910848
[TBL] [Abstract][Full Text] [Related]
29. Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.
Liu B; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37863. PubMed ID: 38669385
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Geriatric Nutritional Risk Index in Patients With Synchronous Colorectal Liver Metastasis.
Iguchi T; Sugimachi K; Mano Y; Motomura T; Sugiyama M; Ota M; Ikebe M; Esaki T; Yoshizumi T; Morita M; Mori M; Toh Y
Anticancer Res; 2020 Jul; 40(7):4165-4171. PubMed ID: 32620666
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi M; Akuta N; Okubo S; Matsumura M; Suzuki Y; Hashimoto M
J Gastrointest Surg; 2022 Aug; 26(8):1637-1646. PubMed ID: 35715641
[TBL] [Abstract][Full Text] [Related]
33. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
Karayama M; Inoue Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
BMC Pulm Med; 2021 Dec; 21(1):409. PubMed ID: 34895201
[TBL] [Abstract][Full Text] [Related]
34. The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery.
Sasaki M; Miyoshi N; Fujino S; Ogino T; Takahashi H; Uemura M; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
Sci Rep; 2020 Jul; 10(1):10744. PubMed ID: 32612136
[TBL] [Abstract][Full Text] [Related]
35. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
Hayashi T; Shibata M; Oe S; Miyagawa K; Honma Y; Harada M
PLoS One; 2020; 15(12):e0244370. PubMed ID: 33351844
[TBL] [Abstract][Full Text] [Related]
36. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Rapposelli IG; Tada T; Shimose S; Burgio V; Kumada T; Iwamoto H; Hiraoka A; Niizeki T; Atsukawa M; Koga H; Hirooka M; Torimura T; Iavarone M; Tortora R; Campani C; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Giuseppe Foschi F; Silletta M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Tanaka T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Rimini M; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
Liver Int; 2021 Dec; 41(12):2997-3008. PubMed ID: 34250737
[TBL] [Abstract][Full Text] [Related]
37. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
38. Geriatric nutritional risk index as a nutritional and survival risk assessment tool in stable outpatients with systolic heart failure.
Sargento L; Vicente Simões A; Rodrigues J; Longo S; Lousada N; Palma Dos Reis R
Nutr Metab Cardiovasc Dis; 2017 May; 27(5):430-437. PubMed ID: 28438373
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center.
Cosma LS; Weigand K; Müller-Schilling M; Kandulski A
J Gastrointestin Liver Dis; 2021 Jun; 30(2):247-253. PubMed ID: 33951122
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
Wang DX; Yang X; Lin JZ; Bai Y; Long JY; Yang XB; Seery S; Zhao HT
World J Gastroenterol; 2020 Aug; 26(30):4465-4478. PubMed ID: 32874058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
